Trends in New Oncology Target Treatments

10:00 AM - 11:00 AM (PDT), Tuesday, October 13, 2020
By 2035, it is estimated that 24 million cancer cases will occur on an annual basis. Although recent progress has deepened our understanding of the disease and has also brought on unprecedented new possibilities for personalized medicine, there are still many cancer types for which there are no, or minimally, effective therapy. Producing new effective cancer treatments thus is seriously needed to keep pace with the growing prevalence but the task is a very difficult and costly one, averaging about $1-2 billion to develop a single drug and requiring vested interests by many stakeholders. Where are investors, companies and investigators placing current bets? This panel will conduct a deep-dive on recent advances in oncology drug development, with a focus on new targets as well as new ways of targeting. Officers from leading companies will provide their insights on the most exciting developments.
Moderator
photo
Managing Director, Equity Research — Biotech
Truist Securities
Speakers
photo
Co-Founder and CEO
OncoSynergy
photo
Managing Director, Equity Research — Biotech
Truist Securities
photo
Senior Vice President R&D and Chief Scientific Officer
AbbVie
photo
Managing Director
Vertex Ventures HC
photo
SVP, Research Administration and Industry Relations
University of Texas, MD Anderson Cancer Center